pembrolizumab


( Last Updated : September 23, 2021)
Generic Name:
pembrolizumab
Project Status:
Complete
Therapeutic Area:
Colorectal cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0235-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open November 02, 2020
Call for patient/clinician input closed December 24, 2020
Clarification:

- Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network

Submission received November 30, 2020
Submission accepted December 14, 2020
Review initiated December 15, 2020
Draft CADTH review report(s) provided to sponsor for comment March 08, 2021
Deadline for sponsors comments March 17, 2021
CADTH responses on draft review report(s) provided to sponsor May 03, 2021
Expert committee meeting (initial) May 14, 2021
Draft recommendation issued to sponsor May 31, 2021
Draft recommendation posted for stakeholder feedback June 10, 2021
End of feedback period June 24, 2021
Final recommendation issued to sponsor and drug plans July 09, 2021
Final recommendation posted July 27, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) July 23, 2021
CADTH review report(s) posted September 22, 2021